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13	patients	with	CHC	compared	 to	12	BMI‐matched	healthy	 control	 subjects.	All	








pose	 interstitial	 fluid	 glycerol	 release	 during	 the	 hyperinsulinaemic	 euglycaemic	
clamp.	 Hepatic	 and	muscle	 insulin	 sensitivity	 were	 similar	 between	 patients	 with	
CHC	and	controls.	Following	viral	eradication,	hepatic	insulin	sensitivity	improved	as	
demonstrated	by	 a	 reduction	 in	 endogenous	 glucose	production	 rate.	 In	 addition,	
circulating	NEFA	decreased	with	sustained	virological	response	(SVR)	and	insulin	was	
more	effective	at	suppressing	adipose	tissue	interstitial	glycerol	release	with	a	paral‐
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1  | INTRODUC TION
Hepatitis	C	virus	(HCV)	infection	is	a	global	health	problem	affecting	
170	million	people	that	 leads	to	progressive	 liver	disease	 including	
cirrhosis	 and	 hepatocellular	 carcinoma	 (HCC).	 Chronic	 hepatitis	 C	
(CHC)	is	also	associated	with	metabolic	syndrome.1,2	Type	2	diabe‐
tes	mellitus	 (T2DM)	 is	more	prevalent	 in	 patients	with	CHC‐asso‐






sive,	 with	 some	 studies	 reporting	 the	 liver	 as	 the	 primary	 site6,7 
and	others	 suggest	 extra‐hepatic	 sites,	 namely	 adipose	 tissue	 and	
skeletal	 muscle.8	 Most	 of	 the	 current	 evidence	 studying	 insulin	
resistance	 in	CHC	 is	based	on	homoeostatic	model	 assessment	of	
insulin	resistance	(HOMA‐IR)	which	cannot	distinguish	sites	of	IR9. 
Hepatic	steatosis	and	insulin	resistance	can	limit	treatment	response	
to	 interferon‐based	 therapies.10‐12	 Directly	 acting	 antiviral	 agents	
(DAAs)	have	recently	become	the	standard	of	care	with	high	rates	





a	 significant	metabolic	burden,	we	 investigated	 the	 tissue‐specific	
contributions	 to	 the	 adverse	 metabolic	 phenotype	 in	 CHC	 using	
state‐of‐the‐art	 metabolic	 phenotyping	 techniques.	 Secondly,	 we	
assessed	the	impact	of	curative	treatments	on	liver	function	and	the	
adverse	metabolic	features	associated	with	CHC.	Our	underpinning	
hypothesis	 is	 that	 adipose	 tissue	 insulin	 resistance	 is	 the	 cardinal	
feature	of	the	metabolic	abnormalities	associated	with	chronic	hep‐
atitis	C	and	this	improves	with	viral	eradication.






the	 patients	 were	 excluded	 because	 their	 treatment	 was	 delayed	
due	to	the	development	of	directly	acting	antiviral	agents.	Eligibility	
for	 the	 study	 was	 determined	 at	 routine	 national	 health	 service	
appointment	by	 standard	blood	 tests,	 clinical	 history	 and	physical	
examination/observations	 to	 identify	 coexisting	 medical	 illnesses	
or	other	contraindications	 (Supporting	Information	S1	 in	Appendix	
S1).	Patients	received	either	interferon‐containing	or	interferon‐free	
regimen,	which	was	 decided	 by	 the	 clinician	 following	 1‐1	 discus‐
sion.	The	types	and	duration	of	treatment	are	 listed	 in	Supporting	
Information	S2	in	Appendix	S1.	Of	the	thirteen	patients,	11	received	








2.2 | Study design and clinical protocol
All	subjects	were	invited	to	the	Welcome	Trust	Clinical	Research	Unit	
where	 they	 underwent	 a	 two‐step	hyperinsulinaemic	 euglycaemic	
clamp,	adipose	tissue	microdialysis	and	biopsy,	magnetic	resonance	

















At	 08:00	hours	 the	 following	morning,	 fasting	 bloods	 were	 taken	
prior	 to	 starting	 the	 two‐step	 clamp	 procedure	 using	 established	
methodology.19	A	bolus	of	13C‐glucose	(CK	Gas	Ltd,	Hook,	UK)	was	
administered	 (2	mg/kg)	 over	 1	minute	 followed	 by	 constant	 rate	
infusion	 of	 13C‐glucose	 (20	µg/kg/min;	 basal	 phase).	 Two	 hours	
K E Y W O R D S
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after	 starting	 the	clamp,	a	 soluble	 insulin	 infusion	 (Actrapid;	Novo	
Nordisk,	Copenhagen,	Denmark)	was	commenced	 (20	mU/m2/min,	




rate	 changed	 to	maintain	 fasting	 glycaemic	 levels.	 After	 a	 further	





duction	 and	 glucose	 disposal	 were	 calculated	 using	modified	 ver‐
sions	of	the	Steel	equations.20,21
2.2.3 | 2H5‐glycerol infusion
Whole	 body	 lipolysis	was	 assessed,	 by	measuring	 glycerol	 rate	 of	
appearance	 (Gly	 Ra)	 using	 stable	 isotope	 dilution	 methodology.	





insulin	 concentration	 needed	 to	 half‐maximally	 suppress	 Gly	 Ra	
(EC50).
2.2.4 | Subcutaneous adipose tissue (SAT) 
microdialysis and biopsy





described	previously.22	 Thirty	minutes	 after	 starting	 the	 low‐dose	











All	 original	 study	 protocols	 had	 been	 reviewed	 and	 approved	 by	
the	local	National	Research	Ethics	Service	(NRES)	Committee	West	






variables	 are	 reported	 as	 number	 and	 percentages.	Area	 under	 the	
curve	 (AUC)	 analysis	 was	 performed	 using	 the	 trapezoidal	 method	
for	 interstitial	 glycerol	 release	 during	 the	 clamp.	 For	 comparison	 of	
single	variables,	paired	Student's	 t	 tests	were	used	 (or	nonparamet‐
ric	 equivalents	 where	 data	 were	 not	 normally	 distributed).	 Where	






3.1 | Participants’ characteristics and systemic 
insulin sensitivity
Patient	 demographics,	 anthropometry	 and	 baseline	 biochemistry	




3.2 | Differences in peripheral, hepatic and 
adipose tissue insulin sensitivity in CHC patients and 
control subjects
3.2.1 | Systemic insulin sensitivity and 
glucose disposal
Fasting	 glucose	 levels	 were	 similar	 in	 CHC	 and	 control	 subjects	
(4.39	±	0.1	 vs	 4.7	±	0.1	mmol/L,	 P	=	0.08)	 and	 were	 successfully	
maintained	across	the	clamp	(Figure	1A).	In	contrast,	fasting	insulin	
and	homoeostatic	model	assessment	for	insulin	resistance	(HOMA‐
IR)	were	 significantly	 increased	 in	 the	CHC	group	 consistent	with	
systemic	insulin	resistance.
Despite	 insulin	 infusion	 rates	 being	 similar	 between	 the	 two	
groups,	 low‐	 and	 high‐dose	 insulin	 concentrations	 were	 higher	 in	
the	CHC	group	(Figure	1B).	Glucose	utilization	under	high‐dose	in‐






tion	 (EGP),	 reflecting	 hepatic	 insulin	 sensitivity	 and	measured	 fol‐
lowing	 low‐dose	 insulin	 infusion,	 was	 similar	 between	 CHC	 and	
4  |     LIM et aL.






HCV	 Gt1	 infected	 patients,	 the	 remaining	 Gt3	 patients	 showed	
increased	 hepatic	 lipid	 content	 compared	 to	 the	 control	 subjects	
(5.2	±	2.4	vs	0.8	±	0.3%,	P	=	0.01)	(Figure	2A).
Fasting	 circulating	NEFA	 levels	were	 similar	 between	CHC	pa‐
tients	 and	 control	 subjects	 in	 the	 basal	 and	 insulinaemic	 states	
(Figure	 2B).	 Ra	 glycerol,	 reflecting	 global	 lipolytic	 rates,	 was	 sup‐





function	 of	 subcutaneous	 abdominal	 adipose	 tissue	 (SAT).	 Insulin	
suppressed	adipose	tissue	 interstitial	 fluid	glycerol	concentrations;	
however,	the	magnitude	of	this	suppression	following	low‐dose	in‐
sulin	 infusion	was	 comparable	 between	CHC	patients	 and	 control	
subjects.	 However,	 endorsing	 our	 observations	 with	 systemic	 Ra	
Glycerol,	 high‐dose	 insulin	 failed	 to	 suppress	 abdominal	 SAT	glyc‐
erol	 release	 in	 CHC	 (54	±	29	 vs	 179	±	26	μmol/kg/min,	 P	=	0.013)	
(Figure	2D).
3.3 | The impact of HCV eradication on liver 
chemistry, body composition and systemic insulin 
sensitivity
Body	 composition	 and	metabolic	 parameters	 including	 BMI,	weight,	
total	 and	android/gynoid	 fat	mass	and	serum	 lipids	were	unchanged	
before	 or	 after	 antiviral	 therapy.	 Alanine	 aminotransferase	 and	 as‐




3.4 | Viral eradication in CHC patients improves 
hepatic and adipose tissue insulin resistance





the	 circulating	 triglyceride	 pool	 (5.6	±	4.3	 vs	 4.3	±	4.7%,	P	=	0.68).	
Fasting	 circulating	 NEFA	 levels	 were	 reduced	 following	 viral	 cure	
(112	±	42	vs	80	±	39	μmol/L,	P	<	0.001).	Although	NEFA	levels	were	
suppressed	by	 low‐	and	high‐dose	 insulin	 infusions,	 there	were	no	










press	 local	 SAT	 glycerol	 release	 (99	±	23	 vs	 71	±	25	μmol/kg/min,	
P	<	0.05),	independent	of	CHC	genotype	(Figure	4C).
3.5 | HCV cure increases transcript levels of 
lipogenic and insulin signalling genes in subcutaneous 
adipose tissue
mRNA	 levels	 of	 genes	 involved	 in	 the	metabolic	 pathways	 includ‐
ing	 insulin	 sensitivity	 and	 lipid	 metabolism	 were	 analysed	 in	 SAT	
using	 a	 Fluidigm	 BioMark	 HD	 System	 96.96	 Dynamic	 Array,	 San	
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Francisco,	CA,	USA	34	of	 the	58	 genes	 showed	 significant	 differ‐
ences	in	expression	levels	before	and	after	viral	eradication;	13	were	
involved	 in	 lipid	metabolism	 (Figure	5A)	 and	7	 in	 insulin	 signalling	
(Figure	5B)	(Supporting	Information	S3	in	Appendix	S1).	Specifically,	
mRNA	 levels	of	diacylglycerol	O‐acyltransferase‐1	 (DGAT1),	 leptin	
(LEP)	 and	 sterol	 regulatory	 element	 binding	 transcription	 factor‐1	
(SREBF1),	 the	 major	 regulator	 of	 lipogenic	 gene	 expression,	 were	
increased	 (2.4‐,4.8‐	 and	 3.5‐fold,	 respectively).	 mRNA	 expression	






































1	 (DUSP1)	 were	 also	 increased	 (5.9‐	 and	 2.3‐fold,	 respectively).	





abolic	 phenotype	 characterized	 by	 systemic,	 hepatic	 and	 adipose	
tissue	IR	This	is	the	first	longitudinal	study	that	has	measured	both	




The	 association	 between	 HCV	 infection	 and	 T2DM	 is	 in‐
dependent	 of	 the	 presence	 of	 cirrhosis.23	 In	 vitro	 studies	 have	
demonstrated	 that	 HCV	 hijacks	 the	 lipid‐producing	 machinery	 of	
hepatocytes	for	its	benefit,	resulting	in	hepatic	steatosis	and	insulin	
resistance.	However,	 liver	cirrhosis	 (regardless	of	aetiology)	 is	also	






to	 control,	 despite	 being	well	 nourished	 and	 of	 normal	 BMI.	 This	
finding	 is	 similar	 to	 the	 observations	 by	Dai	 et	 al.26	 The	 associa‐
tion	between	HCV	and	hypobetalipoproteinaemia,27,28	in	part,	may	
explain	 the	observation.	However,	we	did	not	observe	 increase	 in	
triglyceride	 level	 following	viral	 eradication.	There	was	 significant	
hyperinsulinaemia	in	the	CHC	group	compared	to	control	subjects	
in	this	study.	In	patients	with	CHC,	the	presence	of	steatosis	or	ad‐
vanced	 fibrosis	was	 reported	 to	 associate	with	 a	 reduction	 in	he‐







Our	 detailed	 metabolic	 phenotyping	 approach	 has	 allowed	 us	
to	dissect,	in	a	tissue‐specific	manner,	the	contribution	of	individual	
tissues	to	the	systemic	insulin	resistance	reported	in	HCV‐infected	






largely	 unknown.	 The	 majority	 of	 studies	 published	 to‐date	 have	
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To	the	best	of	our	knowledge,	this	 is	the	first	study	to	demon‐


















concentrations,	we	 showed	 that	patients	with	CHC	had	 increased	
abdominal	 SAT‐specific	 insulin	 resistance	 compared	 to	 BMI‐	 and	
age‐matched	controls.























Our	 study	 is	 not	 without	 limitations.	 Comparison	 between	 a	
mixed	 gender	 CHC	 cohort	 and	 a	 purely	male	 control	 cohort	may	
have	 underestimated	 the	 degree	 of	 insulin	 resistance	 in	 the	CHC	
group,	as	male	subjects	are	perceived	to	have	higher	 insulin	resis‐
tance	due	 to	 the	greater	amounts	of	visceral	 and	hepatic	adipose	
tissue,	and	lack	the	protective	effect	of	oestrogen.39	The	number	of	
participants	is	small	making	it	difficult	to	extrapolate	the	relevance	







visceral	 adipose	 tissue	 function	 are	not	 feasible	 in	human	 studies	
and	therefore	we	have	had	to	extrapolate	our	findings	from	the	SAT	
depot.	Not	all	CHC	patients	received	the	same	antiviral	therapies.	
Pegylated	 interferon	 has	 been	 shown	 to	 alter	 insulin	 sensitivity	






This	 study	 demonstrated	 that	 CHC	 is	 intricately	 linked	 to	 insulin	
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